Treatment Efficacy of MEDI3902 in Pseudomonas aeruginosa Bloodstream Infection and Acute Pneumonia Rabbit Models

Pseudomonas aeruginosa is a challenge for clinicians due to increasing drug resistance and dwindling treatment options. We report on the activity of MEDI3902, an antibody targeting type 3 secretion protein PcrV and Psl exopolysaccharide, in rabbit bloodstream and lung infection models. MEDI3902 prop...

Descripción completa

Detalles Bibliográficos
Autores principales: Le, Hoan N., Tran, Vuvi G., Vu, Trang T. T., Gras, Emmanuelle, Le, Vien T. M., Pinheiro, Marcos Gabriel, Aguiar-Alves, Fábio, Schneider-Smith, Erika, Carter, Henry Clay, Sellman, Bret R., Stover, C. Kendall, DiGiandomenico, Antonio, Diep, Binh An
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2019
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6658784/
https://www.ncbi.nlm.nih.gov/pubmed/31160288
http://dx.doi.org/10.1128/AAC.00710-19
Descripción
Sumario:Pseudomonas aeruginosa is a challenge for clinicians due to increasing drug resistance and dwindling treatment options. We report on the activity of MEDI3902, an antibody targeting type 3 secretion protein PcrV and Psl exopolysaccharide, in rabbit bloodstream and lung infection models. MEDI3902 prophylaxis or treatment was protective in both acute models and exhibited enhanced activity when combined with a subtherapeutic dose of meropenem. These findings further support MEDI3902 for the prevention or treatment of serious P. aeruginosa infections.

Ejemplares similares